Elucidation of DnaE as the antibacterial target of the natural product, nargenicin

Chemistry and Biology

Volumn 22, Issue 10, 2015, Pages 1362-1373

  Painter, Ronald E ^a   Adam, Gregory C ^a   Arocho, Marta ^a   DiNunzio, Edward ^a   Donald, Robert G K ^a   Dorso, Karen ^a   Genilloud, Olga ^b,c   Gill, Charles ^a   Goetz, Michael ^a,d   Hairston, Nichelle N ^a   Murgolo, Nicholas ^a   Nare, Bakela ^a   Olsen, David B ^a   Powles, Maryann ^a   Racine, Fred ^a   Su, Jing ^a   Vicente, Francisca ^b,c   Wisniewski, Douglas ^a   Xiao, Li ^a   Hammond, Milton ^a   Young, Katherine ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b Medical affairs Merck sharp and Dohme ltd   (Spain)

^c Health Sciences Technology Park   (Spain)

^d Natural Products Discovery Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTOGLOBULIN; CIPROFLOXACIN; DACTINOMYCIN; DNA POLYMERASE; DNAE POLYMERASE; ECHINOMYCIN; FOSFOMYCIN; LEVOFLOXACIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOMYCIN; NARGENICIN A1; NATURAL PRODUCT; OXACILLIN; RUFOCROMOMYCIN; STREPTOMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; WARFARIN; ANTIINFECTIVE AGENT; DNA DIRECTED DNA POLYMERASE; DNA DIRECTED DNA POLYMERASE GAMMA; DNA POLYMERASE III, ALPHA SUBUNIT; LACTONE; NUCLEIC ACID SYNTHESIS INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL ASSAY; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA BINDING; DNA HYBRIDIZATION; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; DNA SYNTHESIS INHIBITION; DNA TEMPLATE; ENZYME ACTIVITY; ENZYME ASSAY; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION ZONE; LIMIT OF DETECTION; MACROMOLECULE; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; ANTIBIOTIC RESISTANCE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; IC50; METABOLISM; MUTATION;

ANTI-BACTERIAL AGENTS; DNA POLYMERASE III; DNA REPLICATION; DNA-DIRECTED DNA POLYMERASE; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; INHIBITORY CONCENTRATION 50; LACTONES; MUTATION; NUCLEIC ACID SYNTHESIS INHIBITORS; STAPHYLOCOCCUS AUREUS;

EID: 84950255297     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2015.08.015     Document Type: Article

References (59)

1. Adam, G.C., Parish, C.A., Wisniewski, D., Meng, J., Liu, M., Calati, K., Stein, B.D., Athanasopoulos, J., Liberator, P., Roemer, T., et al. (2008). Application of affinity selection mass spectrometry to determine the structural isomer of parnafungins responsible for binding polyadenosine polymerase. J. Am. Chem. Soc. 130, 16704-16710.
2. Aiello, D., Barnes, M.H., Biswas, E.E., Biswas, S.B., Gu, S., William, J.D., Bowlin, T.L., and Moir, D.T. (2009). Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases. Bioorg. Med. Chem. 17, 4466-4476.
3. Bailey, S., Wing, R.A., and Steitz, T.A. (2006). The Structure of T. aquaticus DNA polymerase III is distinct from eukaryotic replicative DNA polymerases. Cell 126, 893-904.
4. Barnes, M.H., Butler, M.M., George, E., Wright, G.E., and Brown, N.C. (2012). Antimicrobials targeted to the replication-specific DNA polymerases of grampositive bacteria: target potential of DnaE. Infect. Disord. Drug Targets 12, 327-331.
5. Bateman, K.P., Castonguay, G., Xu, L., Rowland, S., Nicoll-Griffith, D.A., Kelly, N., and Chan, C.-C. (2001). Reduction of animal usage by serial bleeding of mice for pharmacokinetic studies: application of robotic sample preparation and fast liquid chromatography-mass spectrometry. J. Chromatogr. B 754, 245-251.
6. Bax, B.D., Chan, P.F., Eggleston, D.S., Fosberry, A., Gentry, D.R., Gorrec, F., Giordano, I., Hann, M.M., Hennessy, A., Hibbs, M., et al. (2010). Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466, 935-940.
7. Brotz-Oesterhelt, H., Knezevic, I., Bartel, S., Lampe, T., Warnecke-Eberz, U., Ziegelbauer, K., Habich, D., and Labischinski, H. (2003). Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones. J. Biol. Chem. 278, 39435-39442.
8. Brown, F.G., May-Dracka, T.L., Gagnon, M.M., and Tommasi, R. (2014). Trends and exceptions of physical properties on antibacterial activity for gram-positive and gram-negative pathogens. J. Med. Chem. 57, 10144-10161.
9. Butler, M.M., and Wright, G.E. (2008). A method to assay inhibitors of DNA polyermase IIIC activity. Methods Mol. Med. 142, 25-36.
10. Celmer, W.D., Chmurny, G.N., Moppet, C.E., Ware, R.S., Watts, P.C., and Whipple, E.B. (1980). Structure of natural antibiotic CP-47,444. J. Am. Chem. Soc. 102, 4203-4209.
11. Clinical and Laboratory Standards Institute. (2005). Methods for Dilution Antibacterial Susceptibility Tests for Bacteria that Grow Aerobically - 7th Edition. Approved Standard M7-a7, vol. 23 (CLSI).
12. Clinical and Laboratory Standards Institute. (2015). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement M100-S25 (CLSI).
13. Entenza, J.M., Vouillamoz, J., Glauser, M.P., and Moreillon, P. (1997). Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrobial. Agents Chemother. 41, 1662-1667.
14. Friedman, L., Alder, J.D., and Silverman, J.A. (2006). Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrobial. Agents. Chemother. 50, 2137-2145.
15. Forsyth, R.A., Haselbeck, R.J., Ohlsen, K.L., Yamamoto, R.T., Xu, H., Trawick, J.D., Wall, D., Wang, L., Brown-Driver, V., Froelich, J.M., et al. (2002). A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol. 43, 1387-1400.
16. Gefter, M.L., Hirota, Y., Kornberg, T., Wechsler, J.A., and Barnoux, C. (1971). Analysis of DNA polymerases II and III in mutants of Escherichia coli thermosensitive for DNA synthesis. Proc. Natl. Acad. Sci. USA 68, 3150-3153.
17. Gill, C.J., Abruzzo, G.K., Flattery, A.F., Misura, A.S., Bartizal, K., and Hickey, E.J. (2007). In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection. Antimicrobial. Agents. Chemother. 51, 3434-3436.
18. Gonzalez del Val, A., Platas, G., Arenal, F., Orihuela, J.C., Garcia, M., Hernandez, P., Royo, I., De Pedro, N., Silver, L.L., Young, K., et al. (2003). Novel illudins from Coprinopsis episcopalis (syn. Coprinus episcopalis), and the distribution of illudin-like compounds among filamentous fungi. Mycol. Res. 107, 1201-1209.
19. Hawser, S., Lociuro, S., and Islam, K. (2006). Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. 71, 941-948.
20. Hishida, T., Han, Y.-W., Shibata, T., Kubota, T., Ishino, Y., Iwasaki, H., and Shinagawa, H. (2004). Role of the Escherichia coli RecQ DNA helicase in SOS signaling and genome stabilization at stalled replication forks. Genes Dev. 18, 1886-1897.
21. Huber, J., Donald, R.G.K., Lee, S.H., Wang Jarantow, L., Salvatore, M.J., Meng, X., Painter, R.E., Onishi, H.R., Occi, J., Dorso, K., et al. (2009). Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus. Chem. Biol. 16, 837-848.
22. Infectious Diseases Society of America. (2010). The 10 × '20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50, 1081-1083.
23. Jaffe, A., D'Ari, R., and Norris, V. (1986). SOS-independent coupling between DNA replication and cell division in Escherichia coli. J. Bacteriol. 165, 66-71.
24. Kodali, S., Galgoci, A., Young, K., Painter, R.E., Silver, L.L., Herath, K.B., Singh, S.B., Cully, D., Barrett, J.F., Schmatz, D., and Wang, J. (2005). Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J. Biol. Chem. 280, 1669-1677.
25. Kreuzer, K.N., and Cozzarelli, N.R. (1979). Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth. J. Bacteriol. 140, 424-435.
26. Lamers, M.H., Georgescu, R.E., Lee, S.-G., O'Donnell, M., and Kuriyan, J. (2006). Crystal structure of the catalytic a subunit of E. coli replicative DNA polymerase III. Cell 126, 881-892.
27. Ling, L.L., Schneider, T., Peoples, A.J., Spoering, A.L., Engels, I., Conlon, B.P., Mueller, A., Schaberle, T.F., Hughes, D.E., Epstein, S., et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature 517, 455-459.
28. Liu, B., Lin, J., and Steitz, T.A. (2013). Structure of the PolIIIa-tc-DNA complex suggests an atomic model of the replisome. Structure 21, 658-664.
29. Magerlein, B.J., and Mizsak, S.A. (1982). 9-O-esters of nodusmicin. J. Antibiot. 35, 111-112.
30. Magerlein, B.J., and Reid, R.J. (1982). Synthesis pf 18-deoxynargenicin A1 (antibiotic 367C) from nargenicin-A1. J. Antibiot. 35, 254-255.
31. Mann, P.A., Müller, A., Xiao, L., Pereira, P.M., Yang, C., Lee, S.H., Wang, H., Trzeciak, J., Schneeweis, J., Moreira dos Santos, M., et al. (2013). Murgocil is a highly bioactive staphylococcal-specific inhibitor of the peptidoglycan glycosyltransferase enzyme MurG. ACS Chem. Biol. 8, 2442-2451.
32. O'Donnell, M., and Studwell, P.S. (1990). Total reconstitution of DNA polymerase III holoenzyme reveals dual accessory protein clamps. J. Biol. Chem. 265, 1179-1187.
33. Page, M.G.P., and Bush, K. (2014). Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr. Opin. Pharmacol. 18, 91-97.
34. Payne, D.J., Gwynn, M.N., Holmes, D.J., and Pompliano, D.L. (2007). Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40.
35. Phillips, J.W., Goetz, M.A., Smith, S.K., Zink, D.L., Polishook, J., Onishi, H.R., Salowe, S., Wiltsie, J., Alloco, J., Sigmund, J., et al. (2011). Discovery of kibdelomycin, A potent new class of bacterial Type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus. Chem. Biol. 18, 955-965.
36. Projan, S.J., and Shlaes, D.M. (2004). Antibacterial drug discovery: is it all downhill from here? Clin. Microbiol. Infect. 10, 18-22.
37. Pryor, K.D., and Leiting, B. (1997). High-level expression of soluble protein in Escherichia coli using a His6-tag and maltose-binding-protein double-affinity fusion system. Protein Expr. Purif. 10, 309-319.
38. Pucci, M.J., and Bush, K. (2013). Investigational antimicrobial agents of 2013. Clin. Microbiol. Rev. 26, 792-821.
39. Ricard, M., and Hirota, Y. (1973). Process of cellular division in Escherichia coli: physiological study on thermosensitive mutants defective in cell division. J. Bacteriol. 116, 314-322.
40. Robertson, G.T., Doyle, T.B., Du, Q., Duncan, L., Mdluli, K.E., and Lynch, A.S. (2007). A novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM. J. Bacteriol. 189, 6870-6881.
41. Robinson, A., Causer, R.J., and Dixon, N.E. (2012). Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target. Curr. Drug Targets 13, 352-372.
42. Sanders, G.M., Dallmann, H.G., and McHenry, C.S. (2010). Reconstitution of the B. subtilis replisome with 13 proteins including two distinct replicases. Mol. Cell 37, 273-281.
43. Sievert, D.M., Ricks, P., Edwards, J.R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B., and Fridkin, S. (2013). Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34, 1-14.
44. Silver, L.L. (2013). Antibacterial discovery: problems and possibilities. In Antibiotics, C. Gualerzi, L. Brandi, A. Fabbretti, and C. Pon, eds. (Wiley-VCH Verlag GmbH & Co. KGaA), pp. 23-52.
45. Singh, S.B., Young, K., and Miesel, L. (2011). Screening strategies for discovery of antibacterial natural products. Expert Rev. Anti Infect. Ther. 9, 589-613.
46. Singh, S.B., Dayananth, P., Balibar, C., Garlisi, C.G., Lu, J., Kishii, R., Takei, M., Fukuda, Y., Ha, S., and Young, K. (2015). Kibdelomycin is a bactericidal broadspectrum aerobic antibacterial agent. Antimicrobial. Agents Chemother. 59, 3474-3481.
47. Snyder, W.C., and Rinehart, K.L., Jr. (1984). Biosynthesis of nargenicin and nodusmicin. J. Am. Chem. Soc. 106, 787-789.
48. Srivastava, A., Talaue, M., Liu, S., Degen, D., Ebright, R.Y., Sineva, E., Chakraborty, A., Druzhinin, S.Y., Chatterjee, S., Mukhopadhyay, J., et al. (2011). New target for inhibition of bacterial RNA polymerase: 'switch region'. Curr. Opin. Microbiol. 14, 532-543.
49. United States Department of Health and Human Services and Centers for Disease Control and Prevention. (2013). Antibiotic resistance threats in the United States. http://www.cdc.gov/drugresistance/threat-report-2013/index.html.
50. Vandewiele, D., Fernández de Henestrosa, A.R., Timms, A.R., Bridges, B.A., and Woodgate, R. (2002). Sequence analysis and phenotypes of five temperature sensitive mutator alleles of dnaE, encoding modified α-catalytic subunits of Escherichia coli DNA polymerase III holoenzyme. Mutat. Res. 499, 85-95.
51. Wang, J., Galgoci, A., Kodali, S., Herath, K.B., Jayasuriya, H., Dorso, K., Vicente, F., Gozalez, A., Cully, D., Bramhill, D., and Singh, S.B. (2003). Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. J. Biol. Chem. 278, 44424-44428.
52. Wang, J., Soisson, S.M., Young, K., Shoop, W., Kodali, S., Galgoci, A., Painter, R.E., Parthasarathy, G., Tang, Y.S., Cummings, R., et al. (2006). Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441, 358-361.
53. Wang, J., Kodali, S., Lee, S.H., Galgoci, A., Painter, R.E., Dorso, K., Racine, F., Motyl, M., Hernandez, L., Tinney, E., et al. (2007). Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc. Natl. Acad. Sci. USA 104, 7612-7616.
54. Wing, R.A., Bailey, S., and Steitz, T.A. (2008). Insights into the replisome from the structure of a ternary complex of the DNA polymerase III α-subunit. J. Mol. Biol. 382, 859-869.
55. Wolfson, J.S., and Hooper, D.C. (1989). Fluoroquinolone antimicrobial agents. Clin. Microbiol. Rev. 2, 378-424.
56. Young, K. (2006). In vitro antibacterial resistance selection and quantitation. In Current Protocols in Pharmacology, S.J. Enna, M. Williams, J.F. Barrett, J.W. Ferkany, T. Kenakin, and R.D. Porsolt, eds. (John Wiley & Sons, Inc), 13A.6.1-13A.6.22.
57. Young, K., Jayasuriya, H., Ondeyka, J.G., Herath, K., Zhang, C., Kodali, S., Galgoci, A., Painter, R., Brown-Driver, V., Yamamoto, R., et al. (2006). Discovery of FabH/FabF inhibitors from natural products. Antimicrobial. Agents Chemother. 50, 519-526.
58. Zhi, C., Long, Z., Gambino, J., Xu, W., Brown, N.C., Barnes, M., Butler, M., LaMarr, W., and Wright, G.E. (2003). Synthesis of substituted 6-anilinouracils and their inhibition of DNA polymerase IIIC and gram-positive bacterial growth. J. Med. Chem. 46, 2731-2739.
59. Zhao, X.Q., Hu, J.F., and Yu, J. (2006). Comparative analysis of eubacterial DNA polymerase III alpha subunits. Genomics Proteomics Bioinformatics 4, 203-211.